OKYO (okyopharma.com) Pangali Forward P/E

The seamless operation of OKYO Pharma Limited (OKYO) laboratories is ensured by a diversified pool of international contractors and strict cold chain controls. The trend of the company's forward P/E ratio clearly confirms these processes, with 0.00 serving as the current value of the indicator. The research center in Britain relies on external CDMO partners, while future revenues are projected from therapies for neuropathic corneal pain and dry eye syndrome.
Rincian analitis lan laporan data perusahaan okyopharma.com (OKYO)

For OKYO Pharma Limited (OKYO), whose model relies on low filling costs within a scalable eye drop market, the issuer's forward P/E serves as an indicator of market expectations regarding future earnings. This metric compares current market capitalization with projected income, allowing investors to determine via chart analysis whether the price already includes a premium for the drug's commercial success or if a potential explosive growth remains undervalued.